Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
The Motley Fool
JUNE 30, 2024
Novo Nordisk (NYSE: NVO) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy. While Ozempic is approved by the Food and Drug Administration (FDA) to treat diabetes patients, its sibling medicine Wegovy is prescribed for obesity care.
Let's personalize your content